You are here: Industry Insights > Bluebird

News List

Bluebird taps Gritstone for oncology cell therapy targets fiercebiotech
August 24, 2018
Bluebird bio has teamed up with Gritstone Oncology to access another set of targets for its oncology cell therapies. The deal sees Bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs).
Bluebird, Gritstone inks deal to develop cancer cell therapies biospectrumasia
August 24, 2018
Gritstone Oncology will receive $20M in an upfront payment and an additional $10M in the form of a Series C preferred equity investment.
Bluebird adds targets, $500M in milestones to Medigene TCR pact fiercebiotech
May 16, 2018
Bluebird bio has added two targets and up to €417 million ($500 million) in milestones to its T-cell receptor (TCR) collaboration with Medigene.
bluebird backs own CAR-T prospect, takes option to co-develop with Celgene pharmafile
March 30, 2018
Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes.
Ambitious Bluebird Seeks Three Drug Approvals by 2019 biospace
January 11, 2018
At the J.P. Morgan Healthcare Conference in San Francisco, bluebird bio announced that it expected to file three applications for regulatory approval by the end of 2019
Bluebird bio joins the ABPI as a full member europeanpharmaceuticalreview
September 15, 2017
The Association of the British Pharmaceutical Industry (ABPI) has admitted the American biotech bluebird bio, Inc. as a full member…

Previous page 1 2 Next page